Hemoglobinopathies Treatment Market Size

Statistics for the 2023 & 2024 Hemoglobinopathies Treatment market size, created by Mordor Intelligence™ Industry Reports. Hemoglobinopathies Treatment size report includes a market forecast to 2029 and historical overview. Get a sample of this industry size analysis as a free report PDF download.

Market Size of Hemoglobinopathies Treatment Industry

Hemoglobinopathies Treatment Market Overview
share button
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 7.00 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Hemoglobinopathies Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Hemoglobinopathies Treatment Market Analysis

The global hemoglobinopathies treatment market was studied and projected to grow with a CAGR of nearly 7% over the forecast period. The growth is primarily due to an increase in the cases of hemoglobinopathies, coupled with growing awareness pertaining to hemoglobin disorders. According to the World Health Organization, about 1.1% of the couples globally are at the risk of having a child with hemoglobin disorder and prevalence was estimated at 2.55 per 1000. In addition, the presence of strong product pipeline for the treatment of hemoglobinopathies and continuous efforts from the market players and government in developing the new therapies for the same are anticipated to boost the market growth. However, low awareness related to the hemoglobinopathies in low and some of the middle-income countries is anticipated to hamper the market growth. Moreover, the initiatives such as newborn screening for detection of potential disorders are lead by the government and private organizations are anticipated to fuel the market growth for hemoglobinopathies treatment.

Hemoglobinopathies Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)